drugset / Trial / NCT00545792
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Phase 2
Completed
21 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabGenentech, Inc. · collabLowell General Hospital · collabMassachusetts General Hospital · collabSaint Anne's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is evaluating a drug called avastin in combination with standard radiation as a possible treatment for treatment for recurrent pelvic-confined gynecological cancer (i.e. endometrial, cervical, vulvar, ovarian or vaginal cancers).
Timeline
- Start
- 2007-05
- Primary completion
- 2010-11
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |